China SXT Pharmaceuticals (SXTC) Payables (2018 - 2025)

China SXT Pharmaceuticals' Payables history runs 8 years deep, the most recent figure standing at $4.2 million for Q3 2025.

• In Q3 2025, Payables rose 13.13% year-over-year to $4.2 million; the TTM figure through Sep 2025 stood at $4.2 million (up 13.13% YoY), while the FY2025 annual figure was $3.6 million, up 105.34% from the prior year.
• Payables was $4.2 million for Q3 2025 at China SXT Pharmaceuticals, up from $3.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $4.2 million in Q3 2025 to a low of $1.5 million in Q1 2023.
• Historically, Payables has averaged $3.2 million across 5 years, with a median of $3.5 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Payables plunged 56.22% in 2023, then surged 105.34% in 2025.
• A 5-year view of Payables shows it stood at $3.4 million in 2021, then retreated by 3.15% to $3.3 million in 2022, then grew by 7.26% to $3.5 million in 2023, then advanced by 6.66% to $3.8 million in 2024, then grew by 13.13% to $4.2 million in 2025.
• The last three Payables figures came in at $4.2 million (Q3 2025), $3.6 million (Q1 2025), and $3.8 million (Q3 2024), per Business Quant data.